ClinicalTrials.gg
CompletedNCT00852202Updated Aug 23, 2018Results posted

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

A Phase 2 interventional study of cariprazine and cariprazine in Bipolar Depression, sponsored by Forest Laboratories. Completed at 26 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-23.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Enrollment
6th of 11
234 · median 234
Started
2009
the only one that year
Phase 2
6 of 11
1 open now
Registered
3rd of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 6 in phase 2, and was the 3rd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.

03

Conditions studied

  • Bipolar Depression

Keywords

  • bipolar
  • depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-65 years old
  • Currently meet the criteria for Bipolar I or II Disorder without psychotic features, with a current depressive episode
  • A verified previous manic, hypomanic, or mixed episode
  • Score of 20 or higher on the HAMD-17
  • Score of 2 or higher on Item 1 of the HAMD

Exclusion criteria

Exclusion Criteria:

  • Score greater than 12 on the Young Mania Rating Scale
  • Eight or more episodes of a mood disturbance (depression, mania, hypomania, or mixed state) within the 12 months prior to Visit 1
  • Principal -based diagnosis of an axis I disorder other than bipolar disorder (a secondary diagnosis of comorbid Generalized Anxiety Disorder, Social Anxiety Disorder, or specific phobias is acceptable)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    1

    0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.

    Drug: cariprazine

  • Experimental
    2

    1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.

    Drug: cariprazine

  • Placebo comparator
    3

    Matching placebo capsules, oral administration, once daily dosing.

    Drug: placebo

Interventions

  • Drug: cariprazine (0.25 - 0.75 mg/day)

  • Drug: cariprazine (1.5 - 3.0 mg/day)

  • Drugplacebo

    placebo capsules, oral administration, once daily dosing

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)

    The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Baseline in Clinical Global Impressions-Improvement ( CGI-I )

    The patient was rated on a scale from 1 to 7, with 1 indicating the patient was very much improved and 7 indicating that the patient was very much worse.

    Time frame: Baseline to Week 8

07

Results

Posted Aug 23, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg Cariprazine
Started777575
Completed606349
Not completed171226
Withdrew: Adverse event237
Withdrew: Lack of efficacy412
Withdrew: Protocol violation227
Withdrew: Withdrawal by subject312
Withdrew: Lost to follow-up556
Withdrew: Pregnancy,moving away and surgery102

Outcome measures

PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)

The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity.

Time frame:
Baseline to Week 8
Reported as:
Mean · Score on scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
Score on scalePlacebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg Cariprazine
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)29.9 ± 0.630.2 ± 0.630.9 ± 0.6
Statistical analysis
  • Placebo vs 0.25 to 0.75 mg Cariprazine · ANCOVA · p = 0.7408
  • Placebo vs 1.5 to 3.0 mg Cariprazine · ANCOVA · p = 0.9961
SecondaryChange in Baseline in Clinical Global Impressions-Improvement ( CGI-I )

The patient was rated on a scale from 1 to 7, with 1 indicating the patient was very much improved and 7 indicating that the patient was very much worse.

Time frame:
Baseline to Week 8
Reported as:
Mean · Score on Scale
Change in Baseline in Clinical Global Impressions-Improvement ( CGI-I )
Score on ScalePlacebo0.25 to 0.75 mg Cariprazine1.5 to 3.0mg Cariprazine
Change in Baseline in Clinical Global Impressions-Improvement ( CGI-I )2.1 ± 0.12.1 ± 0.12.1 ± 0.2
Statistical analysis
  • Placebo vs 0.25 to 0.75 mg Cariprazine · ANCOVA · p = 0.3441
  • Placebo vs 1.5 to 3.0mg Cariprazine · ANCOVA · p = 0.2683

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/77 (2.6%)51/77 (66.2%)
0.25 to 0.75 mg Cariprazine—2/75 (2.7%)48/75 (64%)
1.5 to 3.0 mg Cariprazine—2/75 (2.7%)52/75 (69.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg Cariprazine
Bipolar I disorderPsychiatric disorders0/770/751/75
Suicidal ideationPsychiatric disorders1/770/751/75
Suicidal attemptPsychiatric disorders0/771/750/75
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/771/750/75
DepressionPsychiatric disorders0/770/751/75
Bipolar disorderPsychiatric disorders1/770/750/75
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlacebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg Cariprazine
InsomniaPsychiatric disorders7/7713/7515/75
AkathisiaNervous system disorders5/772/7513/75
HeadacheNervous system disorders12/7711/7512/75
Upper respiratory tract infectionInfections and infestations8/7711/758/75
DiarrhoeaGastrointestinal disorders5/7710/755/75
Dry mouthGastrointestinal disorders4/777/7510/75
NauseaGastrointestinal disorders4/779/759/75
NasopharyngitisInfections and infestations5/777/757/75
FatigueGeneral disorders5/777/756/75
Weight IncreaseInvestigations1/771/756/75

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg CariprazineTotal
Mean40.6 ± 10.737.4 ± 10.738.8 ± 12.138.9 ± 11.2
Age, Customized
Age, Customized(Participants)Placebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg CariprazineTotal
< 201124
20, 3011211850
30, 4024202064
40, 5023232066
50, 6017101340
≥ 601023
Sex/Gender, Customized
Sex/Gender, Customized(participant)Placebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg CariprazineTotal
Female464851145
Male31272482
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg CariprazineTotal
Hispanic or Latino34613
Not Hispanic or Latino747169214
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo0.25 to 0.75 mg Cariprazine1.5 to 3.0 mg CariprazineTotal
Caucasian545662172
Non-Caucasian23191355
Black19161146
Asian2215
Other2114
American Indian or Alaska Native0000
Native Hawaiian or Other Pacific Islander0000
08

Study locations

26 sites
  • Forest Investigative Site 005
    Encino, California 91316, United States
  • Forest Investigative Site 017
    Garden Grove, California 92845, United States
  • Forest Investigative Site 027
    National City, California 91950, United States
  • Forest Investigative Site 013
    Newport Beach, California 92660, United States
  • Forest Investigative Site 010
    Oceanside, California 92056, United States
  • Forest Investigative Site 020
    Bradenton, Florida 34208, United States
  • Forest Investigative Site 007
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 019
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 026
    Orlando, Florida 32806, United States
  • Forest Investigative Site 012
    West Palm Beach, Florida 33407, United States
  • Forest Investigative Site 024
    Glen Burnie, Maryland 21061, United States
  • Forest Investigative Site 029
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site 002
    Omaha, Nebraska 68131, United States
  • Forest Investigative Site 028
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site 001
    Bronx, New York 10467, United States
  • Forest Investigative Site 018
    Durham, North Carolina 27710, United States
  • Forest Investigative Site 004
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 022
    Mason, Ohio 45040, United States
  • Forest Investigative Site 015
    Portland, Oregon 97210, United States
  • Forest Investigative Site 006
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site 011
    Philadelphia, Pennsylvania 19107, United States
  • Forest Investigative Site 014
    Nashville, Tennessee 37212, United States
  • Forest Investigative Site 023
    Irving, Texas 75062, United States
  • Forest Investigative Site 003
    Woodstock, Vermont 05091, United States
  • Forest Investigative Site 009
    Bellevue, Washington 98004, United States
  • Forest Investigative Site 016
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020 Feb 15;263:386-395. doi: 10.1016/j.jad.2019.11.098. Epub 2019 Nov 22. PubMed 31969269 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2009 to primary completion in Jun 2010, 11 months.

Results were first posted in Aug 2018, 8 years 2 months after primary completion. A results delay was requested in Jul 2011.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 60. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2009
First posted
Feb 26, 2009
StartActual
Jun 30, 2009
Primary completionActual
Jun 15, 2010
CompletionActual
Jun 15, 2010
Results delay requested
Jul 6, 2011
Results first posted
Aug 23, 2018
Last update
Aug 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00852202
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Feb 26, 2009
Start date
Jun 30, 2009
Primary completion
Jun 15, 2010
Completion
Jun 15, 2010
Results posted
Aug 23, 2018
Last update
Aug 23, 2018

Study contacts

William Greenberg, MD
study director · Forest Research Institute, a subsidiary of Forest Laboratories, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion